A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. METHODS: In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks. The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation) without worsening of fibrosis; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. Secondary end points included resolution of NASH and regression of fibrosis. RESULTS: A total of 247 patients underwent randomization, of whom 103 (42%) had type 2 diabetes mellitus and 188 (76%) had significant (moderate) or advanced fibrosis. The percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs. placebo, 55% vs. 33%, P = 0.007; 800-mg dose vs. placebo, 48% vs. 33%, P = 0.07). The results favored both the 1200-mg and 800-mg doses of lanifibranor over placebo for resolution of NASH without worsening of fibrosis (49% and 39%, respectively, vs. 22%), improvement in fibrosis stage of at least 1 without worsening of NASH (48% and 34%, respectively, vs. 29%), and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% and 25%, respectively, vs. 9%). Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups. The dropout rate for adverse events was less than 5% and was similar across the trial groups. Diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo. CONCLUSIONS: In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both have been tested successfully on phase II clinical trials, proving they are well-tolerated by patients and showing MASH resolution without worsening of fibrosis (165, 166).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [166]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most importantly, resolution of NASH without worsening of fibrosis (49% with 1200 mg Lanifibranor, vs. 39% with 800 mg vs. 22% Placebo), improvement in fibrosis of at least one stage without worsening of NASH (48% vs. 34% vs. 22%) and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% vs. 25% vs. 9%) all favored the study drug as compared to placebo.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The pan-PPAR agonist lanifibranor demonstrated significant MASH resolution and fibrosis improvement in clinical trials, though it was associated with weight gain [3,136].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [136]
The cited source says what the claim attributes to it.
In the citing paper
“Diarrhea, nausea, peripheral edema, anemia and weight gain were all seen more frequently in patients receiving Lanifibranor [59].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Finally and most recently the Pan‐PPAR agonist Lanifibranor reached the primary endpoint of a decrease in SAF‐A score of at least two points in a large Phase 2b Trial [59]—a dose‐dependent effect was seen with more patients achieving the primary endpoint with 1200 mg versus 800 mg.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 4×
“Increase in aminotransferase level§§ 3 (4) 5 (6) 1 (1)”
InfluentialSelf-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citationNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki-Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,259 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Self-citationFriedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Self-citation
Research works printed but not linked: 2
- Sanyal AJ, Anstee QM, Trauner M, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (NASH). Hepatology 2020; 72: 67A-68A. abstract 90.
- Ratziu V, de Guevara L, Safadi R, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double- blind, placebo-controlled phase 2b trial. Nat Med (in press).
Cited by
Items 201–300 of 830
At the Crossroads of Health and Disease: Consequences of Fat in the Liver
Dukewich, M., Yuan, L., & Terrault, N. A. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105515 · Cited by 38
Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos
Lee, C. J. M., Kosyakovsky, L. B., Khan, M. S., Wu, F., Chen, G., Hill, J. A., Ho, J. E., Foo, R., & Zannad, F. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325602 · Cited by 39
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 37
Mammalian mitohormesis: from mitochondrial stressors to organismal benefits
Gunawan, A. L., Liparulo, I., & Stahl, A. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00549-3 · Cited by 36
MASLD, MASH, and the CKM Spectrum
Zannad, F. M., Khan, M. S., Bansal, N., Böhm, M., Francque, S., Girerd, N., Januzzi, J. L., Miller, V., Piché, M., Ratziu, V., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.015 · Cited by 40
Self-citationHFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
“PPAR agonists, particularly pioglitazone, improved steatohepatitis and liver fibrosis in RCTs 417–419 , with similar findings for the pan-PPAR agonist lanifibranor in a phase IIb trial 420 .”
Statins in Non-alcoholic Steatohepatitis
Torres-Peña, J. D., Martín‐Piedra, L., & Fuentes, F. J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.777131 · Cited by 34
“This PPARs receptor became an attractive target to treat NAFLD/NASH and clinical trials are ongoing to evaluate the effect of PPAR agonists in these diseases (21).”
BackgroundFibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges
Tian, H., Zhang, S., Liu, Y., Wu, Y., & Zhang, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054583 · Cited by 34
Honda, A., Kamata, S., Akahane, M., Machida, Y., Uchii, K., Shiiyama, Y., Habu, Y., Miyawaki, S., Kaneko, C., Oyama, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094726 · Cited by 32
“Saroglitazar (α/γ dual) and lanifibranor (α/δ/γ pan) are currently in clinical trials [16,17].”
BackgroundDai, W., Cai, D., Zhou, S., Li, A., Xie, J., & Zhang, J. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1276790 · Cited by 33
Oligonucleotide therapies for nonalcoholic steatohepatitis
Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 35
Metabolic reprogramming of immune cells in MASH
Ma, C., Wang, S., Dong, B., & Tian, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001371 · Cited by 36
Muthiah, M. D., Ng, C. H., Xiao, J., Chin, Y. H., Lim, G., Lim, W. H., Tay, P. W. L., Tan, D. J. H., Yong, J. N., Pan, X., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16808 · Cited by 32
Self-citationEsteatohepatitis no alcohólica
Romero‐Gómez, M. (2022) · Medicina Clínica · doi:10.1016/j.medcli.2022.06.017 · Cited by 36
Self-citationLiao, Y., Wang, L., Liu, F., Zhou, Y., Lin, X., Zhao, Z., Xu, S., Tang, D., Jiao, Y., Yang, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1078149 · Cited by 35
Cell metabolism-based therapy for liver fibrosis, repair, and hepatocellular carcinoma
Gilgenkrantz, H., Paradis, V., & Lotersztajn, S. (2023) · Hepatology · doi:10.1097/hep.0000000000000479 · Cited by 37
“…HSCs are also important mediators of liver regeneration, [124,125] not only through their production of growth factors particularly HGF, and cytokines such as IL-6, but also because they are the main source of metalloproteinases and inhibitors involved in remodeling the extracellular matrix.”
Unagolla, J. M., Das, S., Flanagan, R., Oehler, M., & Menon, J. U. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124381 · Cited by 33
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 33
Rinella, M. E., & Sookoian, S. C. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01187-8 · Cited by 34
“Among these, the pan-PPAR agonist lanifibranor has shown promising dual efficacy on both MASH resolution and fibrosis improvement in a phase II trial (NCT03008070; n = 247) 117 (Table 1).”
Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease
Chen, C., Li, H., Song, J., Zhang, C., Li, M., Mao, Y., Liu, A., & Du, J. (2022) · PPAR Research · doi:10.1155/2022/4709300 · Cited by 31
“Results from a recent phase 2b clinical trial study showed that the pan-PPAR agonist lanifibranor could modulate key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH, indicating the beneficial effect of the activation of PPARs on NAFLD [17].”
BackgroundLiver fat as risk factor of hepatic and cardiometabolic diseases
Demir, M., Bornstein, S. R., Mantzoros, C. S., & Perakakis, N. (2023) · Obesity Reviews · doi:10.1111/obr.13612 · Cited by 31
“9%) on placebo, indicating promising effects on steatosis with a short-term treatment.(185) A phase III trial on NASH is ongoing.”
BackgroundSuresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Ng, Z. C., Mehta, P. D., Brar, A. S., Sohal, A., Goyal, M. K., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.113149 · Cited by 35
Obesity Management in the Primary Prevention of Hepatocellular Carcinoma
Zunica, E. R. M., Heintz, E. C., Axelrod, C. L., & Kirwan, J. P. (2022) · Cancers · doi:10.3390/cancers14164051 · Cited by 32
NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
Cernea, S. (2024) · Life · doi:10.3390/life14020272 · Cited by 36
Çebi, M., & Yilmaz, Y. N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1445634 · Cited by 30
Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics
Karsdal, M. A., Cox, T. R., Parker, A. L., Willumsen, N., Sand, J. M. B., Jenkins, G. R., Hansen, H. H., Oldenburger, A., Geillinger‐Kästle, K. E., Larsen, A. T., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061856 · Cited by 31
“…mechanisms (such as anti-inflammatory effects and reduction of oxidative stress) and direct actions. pan-PPAR agonist lanifibranor has demonstrated efficacy in modulating both metabolic–immune markers [95] and fibrosis [96] in patients with metabolic dysfunction-associated steatohepatitis (MASH).”
Zhou, Z., Jin, R., Gu, Y., Ji, Y., Lou, Y., & Wu, J. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s524893 · Cited by 31
Present and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 35
“Despite the rigor of this trial, it should be noted that the study population included patients with MASH but not decompensated cirrhosis, and the follow-up was limited to histological endpoints [180].”
Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink
Fernandez, C. J., Alkhalifah, M. K., Afzar, H., & Pappachan, J. M. (2024) · Pathogens · doi:10.3390/pathogens13010068 · Cited by 35
“…for steatohepatitis are currently being developed, such as semaglutide [68], lanifibranor (pan-peroxisome proliferator-activated receptor agonist) [69], resmetirom (selective thyroid hormone receptor-β agonist) [70,71] and obeticholic acid (selective farnesoid X receptor agonist) [72,73], with…”
BackgroundCurrent Landscape and Evolving Therapies for Primary Biliary Cholangitis
Fiorucci, S., Urbani, G., Giorgio, C. D., Biagioli, M., & Distrutti, E. (2024) · Cells · doi:10.3390/cells13181580 · Cited by 31
“Consequently, the recommended dosage was determined to be 280 mg/m 2 /4 h.”
BackgroundA phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH
Harrison, S. A., Alkhouri, N., Ortiz‐Lasanta, G., Rudraraju, M., Tai, D., Wack, K., Shah, A., Besuyen, R., Steineger, H. H., Fraser, D. A., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.032 · Cited by 30
Self-citationBile acid signaling in MASLD: From pathogenesis to therapeutic applications
Simbrunner, B., Paternostro, R., Reiberger, T., & Trauner, M. (2025) · Hepatology · doi:10.1097/hep.0000000000001539 · Cited by 33
Misra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 28
PPAR-δ: A key nuclear receptor in vascular function and remodeling
Xiao, L., & Wang, N. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.04.019 · Cited by 32
Pregnancy and Metabolic-associated Fatty Liver Disease: A Clinical Update
Fouda, S., Vennikandam, M. M., Pappachan, J. M., & Fernandez, C. J. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00052 · Cited by 31
Huai, Q., Zhu, C., Zhang, X., Dai, H., Li, X., & Wang, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01122-3 · Cited by 28
“At present, conventional molecular drugs for liver diseases have displayed some limitations, such as adverse drug reactions, insensitivity to some medicines, and drug resistance [141, 142].”
BackgroundHepatic adaptation to chronic metabolic stress primes tumorigenesis
Tzouanas, C. N., Shay, J. E. S., Sherman, M. S., Rubin, A. J., Mead, B. E., Dao, T. T., Tao, J., Lehrich, B. M., Eng, G. M., Patterson-Fortin, J., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.031 · Cited by 39
Emerging targets for therapy in ALD: Lessons from NASH
Singal, A. K., Shah, V. H., & Malhi, H. (2023) · Hepatology · doi:10.1097/hep.0000000000000381 · Cited by 28
Current, emerging, and potential therapies for non-alcoholic steatohepatitis
Yang, Z. L., & Wang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152042 · Cited by 32
“A phase IIb trial involving patients with active NASH showed that lanifibranor remarkably improved NASH without worsening fibrosis (Francque et al., 2021).”
BackgroundExploring the links between types 2 diabetes and liver‐related complications: A comprehensive review
Sanchez, L. O., Chen, Y., Lassailly, G., & Qi, X. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12508 · Cited by 28
“107 Insulin remains the preferred choice for managing hyperglycemia in adults with type 2 diabetes complicated by decompensated cirrhosis, primarily due to the limited availability of robust evidence supporting the safety and effectiveness of oral agents and non ‐ insulin injectables, such as…”
BackgroundMacrophage fatty acid oxidation in atherosclerosis
Xiao, S., Qi, M., Zhou, Q., Gong, H.-Q., Wei, D., Wang, G., Feng, Q., Wang, Z., Liu, Z., Zhou, Y., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116092 · Cited by 27
Role of MASLD in CVD: A review of emerging treatment options
Mollace, R., Longo, S., Nardin, M., Tavernese, A., Musolino, V., Cardamone, A., & Federici, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111891 · Cited by 29
Wan, X., Ma, J., Bai, H., Hu, X., Ma, Y., Zhao, M., Liu, J., & Duan, J. (2025) · Biomolecules · doi:10.3390/biom15010140 · Cited by 27
Drugs targeting peroxisome proliferator-activated receptors
Xie, Z., Xin, J., Huang, C.-J., & Liao, C. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104318 · Cited by 25
Brar, A. S., Khanna, T., Sohal, A., Hatwal, J., Sharma, V., Singh, C. M., Batta, A., Chandra, P., & Mohan, B. (2026) · World Journal of Cardiology · doi:10.4330/wjc.v18.i1.111954 · Cited by 30
Miao, L., Xu, J., Targher, G., Byrne, C. D., & Zheng, M. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0015 · Cited by 27
Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome
Khan, M. S., Kim, H., Kim, R., Yoon, S. H., & Kim, S. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087454 · Cited by 27
Towards precision medicine in non-alcoholic fatty liver disease
Francque, S. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09820-6 · Cited by 26
“Two phase 3 trials [47, 48] and several phase 2 trials [45, 92] have meanwhile reported positive results with several drugs (Fig.”
BackgroundSelf-citationMao, T., Sun, Y., Xu, X., & He, K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000234 · Cited by 27
“…— √ √ — Zydus Therapeutics Siddiqui et al [271] Gawrieh et al [272] pan-PPAR Lanifibranor (IVA337) Phase 3 NAFLD/NASH — √ NA √ — Sven et al [273] Chiglitazar Phase 2 NASH TBD TBD TBD TBD Chipscreen Biosciences — DPP-4 Sitagliptin Phase 4 (terminated) NAFLD/NASH — — — — — Cui et al [274]…”
Fan, W., Bradford, T. M., & Török, N. J. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15184 · Cited by 25
Molecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease
Burks, K. H., Stitziel, N. O., & Davidson, N. O. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101409 · Cited by 27
Sharma, S., Tiwari, N., & Tanwar, S. S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04069-z · Cited by 35
Mechanisms and therapeutic insights into MASH-associated fibrosis
Zhu, Y., & Cai, B. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.09.004 · Cited by 32
An, J., & Sohn, J. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0437 · Cited by 25
Gaucher, J., Montellier, E., Vial, G., Chuffart, F., Guellerin, M., Bouyon, S., Lemarié, E., Yamaryo‐Botté, Y., Dirani, A., Messaoud, R. B., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108837 · Cited by 25
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 26
“Liver enzyme levels decreased, and various biomarkers improved in the lanifibranor groups [79, 81].”
Antwi, M. B., Jennings, A., Lefere, S., Clarisse, D., Geerts, A. M., Devisscher, L., & Bosscher, K. D. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00013-6 · Cited by 27
Senavirathna, T., Shafaei, A., Lareu, R. R., & Balmer, L. A. (2024) · Antioxidants · doi:10.3390/antiox13040485 · Cited by 25
“A successfully conducted 2b double-blind, randomised, placebo-controlled clinical trial on Lanifibranor [98] identified that patients administered a once-daily dose of 1200 mg demonstrated a significantly higher reduction percentage (55% vs. 33% for placebo) in the SAF-A score (representing the…”
BackgroundMethodKakazu, E., Mino, M., & Kanto, T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0048 · Cited by 28
Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 29
“Lanifibranor, a pan-PPAR (peroxisome proliferator-activated receptor) agonist, also demonstrated improvements in fibrosis and MASH in a phase 2b randomized controlled trial [192].”
Liu, Y., Zhang, M., Huang, Y., Zhang, Y., Chen, Z., Guan, J., Xia, S., & Liao, J. (2025) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02599-w · Cited by 27
“Since MASH is closely related to lipid metabolism disorders and insulin resistance, pan-PPAR agonists like lanifibranor are becoming a promising method for MASH treatment [159, 160].”
Pennisi, G., Celsa, C., Enea, M., Vaccaro, M., Marco, V. D., Ciccioli, C., Infantino, G., Mantia, C. L., Parisi, S., Vernuccio, F., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.07.001 · Cited by 24
Duseja, A. K., De, A., & Wong, V. W. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.011 · Cited by 23
Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review
Tidwell, J., Balassiano, N., Shaikh, A., & Nassar, M. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i8.1001 · Cited by 23
Fiorucci, S., Sepe, V., Biagioli, M., Fiorillo, B., Rapacciuolo, P., Distrutti, E., & Zampella, A. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115776 · Cited by 23
Single-cell multiomics guided mechanistic understanding of Fontan-associated liver disease
Hu, P., Rychik, J. R., Zhao, J., Bai, H., Bauer, A., Yu, W., Rand, E. B., Dodds, K. M., Goldberg, D., Tan, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk6213 · Cited by 29
Kupffer cells in liver homeostasis and disease: from immune sentinels to metabolic gatekeepers
David, B. A., Andreata, F., Blériot, C., Ginhoux, F., Kubes, P., & Iannacone, M. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01288-0 · Cited by 30
“In humans, PPARs are targets of ongoing clinical trials that aim to prevent the inflammatory activation of macrophages 103,104 .”
What’s new in non-alcoholic fatty liver disease?
Spiers, J., Brindley, J. H., Li, W., & Alazawi, W. (2022) · Frontline Gastroenterology · doi:10.1136/flgastro-2022-102122 · Cited by 26
Min, R. W. M., Aung, F. W. M., Liu, B., Arya, A., & Win, S. (2022) · Biomedicines · doi:10.3390/biomedicines10082035 · Cited by 24
Omega-3 pleiad: The multipoint anti-inflammatory strategy
Batista, E. D. S., Nakandakari, S. C. B. R., da Silva, A. S. R., Pauli, J. R., de Moura, L. P., Ropelle, E. R., Camargo, E. A., & Cintra, D. E. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2146044 · Cited by 25
“…cardiovascular functions (Tanaka et al. 2020), energy expenditure (Risérus et al. 2008), liver lipid metabolism in nonalcoholic steato-hepatitis (Francque et al. 2021, Lefere et al. 2020), modulation of innate immunity (Lefere et al. 2020), and NFkB signaling blockade (Zhao, Wang, and Guo…”
BackgroundEmerging Therapeutic Targets for Portal Hypertension
Felli, É., Nulan, Y., Selicean, S. E., Wang, C., Gracia‐Sancho, J., & Bosch, J. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00598-4 · Cited by 24
“Moreover, clinical studies suggest that lanifibranor may promote fibrosis regression in patients with NASH, although further studies are needed to confirm a therapeutic benefit in patients with advanced fibrosis [124].”
BackgroundSGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Xu, R., Lian, D., Xie, Y., Chen, Z., Wang, Y., Mu, L., Wang, Y., & Zhang, B. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807134 · Cited by 25
Pennisi, G., Enea, M., Romero‐Gómez, M., Bugianesi, E., Wong, V. W., Fracanzani, A. L., de Lédinghen, V., George, J., Berzigotti, A., Viganò, M., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000616 · Cited by 22
Self-citationLara, C., & Romero‐Gómez, M. (2024) · European Cardiology Review · doi:10.15420/ecr.2023.34 · Cited by 26
“96 Two more trials to evaluate the efficacy of lanifibranor in concomitant MASLD and type 2 diabetes and advanced fibrosis due to NASH are ongoing.”
BackgroundSelf-citationReview article: vascular effects of PPARs in the context of NASH
Guixé‐Muntet, S., Biquard, L., Szabó, G., Dufour, J., Tacke, F., Francque, S., Rautou, P., & Gracia‐Sancho, J. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17046 · Cited by 22
Self-citationNAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?
Chen, B. Y., Tang, W. H. W., Rodriguez, M., Corey, K. E., Sanyal, A. J., Kamath, P. S., Bozkurt, B., Virk, H. U. H., Pressman, G. S., Lazarus, J. V., et al. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1757712 · Cited by 24
Self-citationShinozaki, S., Tahara, T., Miura, K., Lefor, A. K., & Yamamoto, H. (2022) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2022.120099 · Cited by 25
“Actually, a pan-PPAR agonist showed favorable results with histologic improvement in NASH, but an increase in weight was also observed [16].”
BackgroundNewsome, P. N., Sanyal, A. J., Neff, G. W., Schattenberg, J. M., Ratziu, V., Ertle, J., Link, J., Mackie, A. E., Schoelch, C., Lawitz, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42398-w · Cited by 21
Self-citationAmorim, R., Soares, P., Chavarria, D., Benfeito, S., Cagide, F., Teixeira, J., Oliveira, P. J., & Borges, F. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116723 · Cited by 26
Deckmyn, O., Poynard, T., Bédossa, P., Paradis, V., Peta, V., Pais, R., Ratziu, V., Thabut, D., Brzustowski, A., Gautier, J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030699 · Cited by 23
“Recent phase 2 randomized trials in patients with NAFLD used serum ApoA1 as secondary endpoints for assessing the drug’s benefit [68,95].”
BackgroundMethodSelf-citationNielsen, M. H., Nøhr-Meldgaard, J., Møllerhøj, M. B., Oró, D., Pors, S. E., Andersen, M. W., Kamzolas, I., Petsalaki, E., Vacca, M., Harder, L. M., et al. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00110.2024 · Cited by 22
Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer
Karin, M., & Kim, J. Y. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100096 · Cited by 28
“193”
Fibrosis—the tale of H3K27 histone methyltransferases and demethylases
Basta, M. D., Petruk, S., Mazo, A., & Walker, J. L. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1193344 · Cited by 20
“, 2021) and are currently being used in clinical trials (Francque et al., 2021).”
MethodPharmacotherapies of NAFLD: updated opportunities based on metabolic intervention
Shao, Y., Chen, S., Liu, H., & Liu, J. (2023) · Nutrition & Metabolism · doi:10.1186/s12986-023-00748-x · Cited by 21
Targeting nuclear receptors for NASH/MASH: From bench to bedside
Sinha, R. A. (2024) · Liver Research · doi:10.1016/j.livres.2024.03.002 · Cited by 23
The PD-1/PD-L1 Axis in the Biology of MASLD
Pipitone, R. M., Lupo, G., Zito, R., Javed, A., Petta, S., Pennisi, G., & Grimaudo, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073671 · Cited by 22
“…a pan-PPAR agonist, resulted in a decrease of at least two points in the SAF-A score without a worsening of fibrosis compared to placebo in MASLD in a randomized, controlled, phase IIb clinical trial (NATIVE trial), supporting the further assessment of Lanifibranor in phase III trials [136].”
Honey vesicle-like nanoparticles protect aged liver from non-alcoholic steatohepatitis
Liu, B., Nguyen, P. L., Yu, H., Li, X., Wang, H., Nguyen, T. G. B., Sahoo, P. K., Sur, M., Reddy, J., Sillman, S. J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.002 · Cited by 23
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Khaznadar, F., Khaznadar, O., Petrovic, A., Hefer, M., Gjoni, F., Gjoni, S., Steiner, J., Smolić, M., & Bojanić, K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070376 · Cited by 23
“…RCT (NCT03008070) with a total enrollment of 247 participants, in which lanifibranor showed superiority over placebo in reducing the SAF-A score (activity part of the Steatosis Activity Fibrosis score) by at least two points without deterioration of fibrosis after 24 weeks of therapy [102,103].”
BackgroundTherapeutic Targets and Approaches to Manage Inflammation of NAFLD
Geng, W., Liao, W., Cao, X., & Yang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13020393 · Cited by 20
“Lanifibranor, a pan-PPAR agonist, achieved significant histological and metabolic benefits in a phase IIb trial (NCT03008070) [145], and is undergoing phase III evaluation with FDA breakthrough therapy designation.”
Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
Chang, Y. W., Jeong, S. W., & Jang, J. Y. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0356 · Cited by 22
Gupta, U., Ruli, T. M., Buttar, D., Shoreibah, M., & Gray, M. E. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.11.007 · Cited by 21
Wu, Y., Dong, P., Wu, Q., Zhang, Y., Xu, G., Pan, C., & Tong, H. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3606 · Cited by 20
Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights
Padmanaban, S., Baek, J.-W., Sahithya, C. S., Saipriya, C., Samrot, A. V., Gosu, V., Park, I., Radhakrishnan, K., & Kim, D. (2025) · Liver Research · doi:10.1016/j.livres.2025.04.002 · Cited by 22
Call to action—Pediatric MASLD requires immediate attention to curb health crisis
Hartmann, P., Mouzaki, M., Hassan, S. M., Kehar, M., Mysore, K. R., Mauney, E. E., Nonga, D., Karjoo, S., Sood, S., Tou, A. M., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001440 · Cited by 20
Self-citationNuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights
Zhu, C.-Y., Yu, P., Sun, Q., Hong, D., Yang, C., & Naranmandura, H. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107862 · Cited by 19
Mohamed‐Ezzat, R. A., & Elgemeie, G. H. (2025) · RSC Advances · doi:10.1039/d5ra03993b · Cited by 19
Tissue regeneration: Unraveling strategies for resolving pathological fibrosis
Li, J., Wang, S., Yuan, J., Mao, X., Wang, X., Zhang, L., Dong, Q., Chen, Z., Wang, Y., & Tang, N. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.10.002 · Cited by 23
The many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 20
Self-citationPotential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH)
Wang, Z., Zhao, Z., Xia, Y., Cai, Z., Wang, C., Shen, Y., Liu, R., Qin, H., Jia, J., & Yuan, G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01773-y · Cited by 19
“As a peroxisome proliferator-activated receptor agonist, Lanifibranor improves NASH by regulating metabolism, inflammation, and fibrogenesis [10].”
BackgroundToth, P. P., Schwartz, G. G., Nicholls, S. J., Khan, A., Szarek, M. J., Ginsberg, H. N., Johansson, J. O., Kalantar‐Zadeh, K., Kulikowski, E., Lebioda, K., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100372 · Cited by 21
“Although no drugs are currently approved for treating NAFLD, PPAR activators, which may also favorably influence a dysregulated transcriptional profile, have shown promise [44,45].”
Background
Metadata
- Authors
- Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., Lanthier, N., Alkhouri, N., Moreno, C., Schattenberg, J. M., Stefanova-Petrova, D., Vonghia, L., Rouzier, R., Guillaume, M., Hodge, A., Romero-Gómez, M., Huot-Marchand, P., Baudin, M., Richard, M.-P., Abitbol, J.-L., Broqua, P., Junien, J.-L., & Abdelmalek, M. F.
- Affiliations
- Cliniques Universitaires Saint-Luc (BE)
- From Antwerp University Hospital and the Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp (S.M.F., L.V.), and Service d’Hépato-Gastroentérologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (N.L.) and Cliniques Universitaires de Bruxelles–Hôpital Erasme, Université Libre de Bruxelles (C.M.), Brussels — all in Belgium; the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom (P. Bedossa, Q.M.A.); Pitie–Salpétriêre Hospital, Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris (V.R.), Centre Hospitalier Universitaire Rangueil, Toulouse (M.G.), and Inventiva Pharma, Daix (P.H.-M., M.B., M.-P.R., J.-L.A., P. Broqua, J.-L.J.) — all in France; the Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy (E.B.); Virginia Commonwealth University, Richmond (A.J.S.); the University of California San Diego, La Jolla (R.L.); Pinnacle ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1547-1558
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3207086349
- Cited by
- 801
- References
- 33
- Citations by year
- 2026: 171 · 2025: 197 · 2024: 156 · 2023: 150 · 2022: 119 · 2021: 7
- FWCI
- 77.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by-nc-nd)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Inventiva Pharma S.A., Daix, France
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- lanifibranor, nonalcoholic steatohepatitis, liver fibrosis regression, NASH resolution, type 2 diabetes, dose comparison, liver enzymes, PPAR agonists, fibrosis stage
- MeSH terms
- Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Sulfonamides, Body Mass Index, Peroxisome Proliferator-Activated Receptors, Benzothiazoles, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.